SHAHEED RAJAIE CARDIOVASCULAR MEDICAL CENTER, MELLAT PARK, VALI-ASR AVE., TEHRAN, IRAN
Objective- This randomized, double blind trial was designed to compare the efficacy and safety of ezetimibe, a new cholesterol-lowering agent with atorvastatin (Lipitor), a potent cholesterol inhibitor derivative.
Method- Between September 2004 and March 2005, a total of 120 hyperlipidemic patients, aged 28-80 years, were randomized to receive ezetimibe 10 mg or atorvastatin 10 mg orally daily for 8 weeks after a 4-week washout phase and diet on NCEP step n. Mean changes of serum lipoproteins after 4 and 8 weeks of drug therapy were measured and compared in both groups of patients.
Results- Ezetimibe reduced LDLc and total cholesterol by a mean of 27% and 16% compared with 32% and 24% for atorvastatin, respectively. The difference was not statistically significant. Conclusion- Ezetimibe and atorvastatin both reduced LDLc and TC with no statistically significant difference.